Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
112 hedge funds and large institutions have $187M invested in Provention Bio, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 51 increasing their positions, 18 reducing their positions, and 14 closing their positions.
267% more call options, than puts
Call options by funds: $4.45M | Put options by funds: $1.21M
183% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 18
87% more capital invested
Capital invested by funds: $99.9M → $187M (+$87.1M)
3% less funds holding
Funds holding: 115 → 112 (-3)
21% less first-time investments, than exits
New positions opened: 11 | Existing positions closed: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SC
Sessa Capital
New York
|
+$40.5M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$22.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.68M |
| 4 |
BlackRock
New York
|
+$1.93M |
| 5 |
PAI
Palo Alto Investors
Palo Alto,
California
|
+$1.78M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$617K |
| 2 |
DCM
DG Capital Management
New York
|
-$562K |
| 3 |
Goldman Sachs
New York
|
-$530K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$425K |
| 5 |
JF
Jump Financial
Chicago,
Illinois
|
-$222K |
PRVB Hedge Fund Activity: Q3 2022 in Review
112 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q3 2022, worth a combined $187M — up 87% from $99.9M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of PRVB and 11 opened new positions — a net loss of 3 holders — while 18 trimmed existing stakes and 51 added.
The largest buyer was Sessa Capital, adding an estimated $40.5M. The largest seller was Renaissance Technologies, cutting an estimated $617K.
- 112 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q3 2022, down from 115 in Q2 2022.
- Funds reported $187M of Provention Bio, Inc. Common Stock stock for Q3 2022, up 87% quarter-over-quarter.
- 11 funds opened new Provention Bio, Inc. Common Stock positions in Q3 2022 and 14 closed out, a net change of -3 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q3 2022 was Sessa Capital, an estimated $40.5M added.
- The largest Provention Bio, Inc. Common Stock seller in Q3 2022 was Renaissance Technologies, an estimated $617K sold.
Based on aggregated 13F filings for Q3 2022.